UroCAD Outperforms Urine Cytology in Detecting Urothelial Carcinoma
October 9th 2020This study suggested that the customized bioinformatics workflow, UroCAD, be used as a noninvasive approach for diagnosis and recurrence surveillance in patients with urothelial carcinoma prior to the use of cystoscopy.
Phase 3 PENELOPE-B Trial Fails to Meet Meet Primary End Point for HR+, HER2- Early Breast Cancer
October 9th 2020The trial did not meet its primary end point of improved invasive disease-free survival in women with hormone receptor-positive HER2-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy.
6-Month PFS for 12-Month OS Model Appears Effective for Estimating 12-Month OS
October 7th 2020Researchers suggested these findings may assist in better selection and prioritization of immune checkpoint inhibitor agents for testing in randomized clinical trials based on phase 2 single arm randomized clinical trial results.
Study Identifies Characteristics of CAR T-Cell Products Associated with Outcomes in LBCL
October 7th 2020Researchers identified molecular and cellular characteristics of anti-CD19 CAR T-cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and experience adverse events.
Phase 3 CheckMate-816 Trial Meets Primary End Point in Resectable NSCLC
October 7th 2020Significantly more patients treated with nivolumab (Opdivo) plus chemotherapy before surgery demonstrated no evidence of cancer cells in their resected tissue in the trial compared to those treated with chemotherapy alone.
Jennifer L. Moss, PhD, on Cancer Mortality in Persistent Poverty Counties
October 6th 2020Moss indicated that “we need interventions in these communities to change cancer-causing behaviors, to make cancer screening more accessible, to improve treatment, and to promote quality of life and survivorship.”
Predicting Tumor Response Using Combo of Peritumoral Radiomics Features Appears Effective
October 4th 2020A combination of peritumoral radiomics features appeared to improve the predictive performance of intratumoral radiomics to estimate pathological complete response after neoadjuvant chemoradiation in patients with esophageal squamous cell carcinoma.
Study Supports Pembrolizumab Plus Chemo as Standard of Care for PD-L1-Negative Advanced NSCLC
October 4th 2020A pooled analysis of 3 randomized controlled trials found that pembrolizumab plus chemotherapy demonstrated response and survival improvements with a manageable safety in comparison with chemotherapy alone in PD-L1‒negative advanced non-small cell lung cancer.
Adding Immunotherapy to Radiotherapy May Improve OS in Patients with Brain Metastases
October 3rd 2020This study found that the addition of immunotherapy to radiotherapy was associated with improved overall survival compared with radiotherapy alone in patients with brain metastases who received definitive surgery of the primary tumor site.
Single-dose BIVV001 Appears Safe, Effective for Men with Severe Hemophilia A
October 3rd 2020The study found that high levels of sustained factor VIII activity, which followed a normalization period after BIVV001 administration, might offer better protection against all types of bleeding and a longer interval between administration of the product in this patient population.
Re-Evaluating Standard Clinical Trial Practices as a Result of COVID-19
October 2nd 2020Researchers suggested that the current situation be used as an opportunity to re-evaluate standard practices for clinical trials in order to make them more accessible and less stressful for potential patients and thus allow for broader participation.
Atezolizumab Appears Effective for Patients with NSCLC with High PD-L1 Expression
October 1st 2020The findings from this global, open-label, randomized trial supported the FDA approval of atezolizumab for patients with non-small cell lung cancer with high PD-L1 expression, regardless of histologic type, in May.